Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
In this subgroup analysis of an RCT (n=1,254), 3-month oxaliplatin-based adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPOX) did not show non-inferiority to 6-month fluorouracil, leucovorin, and oxaliplatin (FOLFOX); but 3-month treatment was significantly less toxic
Source:
JAMA Oncology
SPS commentary:
The 5-year relapse-free survival was 82.2% for the 3-month arm and 88.2% for the 6-month arm, with an estimated hazard ratio of 1.41 (95% CI, 1.05-1.89; p=0.86 for non-inferiority).
Authors state that although non-inferiority of the 3-month arm was not shown, a 3-month CAPOX regimen or a 6-month FOLFOX regimen can be selected when choosing adjuvant chemotherapy in stage II colorectal cancer.